Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
Ionis completes enrollment for Cohort 1 of the pivotal Phase 3 REVEAL study evaluating obudanersen for Angelman syndrome. Cohort 2 screening continues for ages 18–50.
Community Update: New Insights into Health and Prevention in Angelman Syndrome
A newly published study explores mortality risks in Angelman syndrome, highlighting key preventive areas like silent aspiration and pneumonia, while providing essential care resources for families.